| |
Like This Page & You Are
Instantly Entered To Win $5,000.00
The Full Report World Wide Research
On Stem Cells
I. INTRODUCTION, METHODOLOGY & PRODUCT
DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Types of Stem Cells I-3
Embryonic Stem Cells I-3
Adult Stem Cells I-3
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW II-1
Overview II-1
Major Achievements Thus Far II-1
A Glimpse of Major Historical Events in the Area of Stem Cell
Research II-1
New Growth Areas II-2
Orthopedic Products - A potential growth sector II-2
Utilitarian Functions of Cord Blood Stem Cells II-2
Umbilical Cord Stem Cells in the Treatment of Hepatic Diseases
II-3
Human Umbilical Cord Blood-Derived Stem Cells in Insulin
Synthesize II-3
Challenges II-3
Stem Cell Research And the Ethical Angle II-3
2. MARKET DYNAMICS AND TRENDS II-4
North America Dominates Global Stem Cells Market II-4
Stem Cells Breakthrough Reshaping the Area of Medicine II-4
Korea Debuts the World's First Somatic Stem Cell-Based Therapy
II-4
New Technologies Draw Significant Attention II-5
Ethical Issues and Nascent Stage - Key Market Restraints for
Stem Cells II-5
Medical Tourism Picks Up in Stem Cell Therapy II-6
Government Regulations Fail to Prevent Medical Tourism in
Stem Cell Therapy II-6
US and Japan Surge Ahead of Europe in Stem Cell Patents II-7
Table 1: Global Stem Cells Patent Analysis by Market (2010):
Percentage Breakdown of Number of Patents Issued for US,
Japan and Europe (includes corresponding Graph/Chart) II-7
Table 2: Global Stem Cells Patent Analysis by Product (2010):
Percentage Breakdown of Number of Patents Issued for Adult
Stem Cells, Human Embryonic Stem Cells, Mesenchymal Stem
Cells, Hematopoietic Stem Cells, Neuronal Stem Cells and
Others (includes corresponding Graph/Chart) II-8
Table 3: Leading Stem Cell Companies by Patents (2010):
Percentage Breakdown of Number of Patents Secured for Geron
Corp., Osiris Therapeutics, Olympus Corporation, Wisconsin
Alumni Research Foundation, Kourion Therapeutics AG, Japan
Science & Tech Agency and Others (includes corresponding
Graph/Chart) II-8
3. STEM CELLS MARKET DYNAMICS - BY TYPE II-9
Adult Stem Cells Hold Tremendous Potential II-9
Adult Stem Cells and Embryonic Stem Cells - A Comparison II-9
A Low Risk Investment II-10
Adult Stem Cells Garner More Investments for Research II-10
Low Versatility - A Major Limiting Factor for Adult Stem Cells
II-10
Hematopoietic Stem Cells - Enjoying Enduring Success II-10
The Restraining Factors II-11
Mesenchymal Stem Cells - A Promising Therapeutic Option II-11
Difficulty in Isolation and Lower Understanding Hampers Growth
II-11
Induced Pluripotent Stem Cells - An Alternative to ESCs II-12
A Peek Into the Discovery of iPS II-12
Drug Development - A Major Application for iPS II-12
Regenerative Medicine II-13
Establishing iPS Cell Banks II-13
Intractable and Congenital Disease Treatments II-13
Repairing Organs II-14
Embryonic Stem Cells to Transfigure the Field of Medicine II-14
Lack of Safety and Efficacy Data Remains A Concern II-14
4. STEM CELLS RESEARCH BY APPLICATION II-15
Stem Cells in Disease Management II-15
Stem Cell Therapy in Regenerative Medicine II-15
Stem Cell Therapy - A Promising Treatment for Neurological
Disorders II-16
Large-Scale Studies Imperative to Substantiate Early Positive
Results In Cardiovascular Diseases II-16
Stem Cell Therapy in Cancer II-16
Stem Cells Set Foot in Personal Care II-17
Aging Population to Drive Orthopedic Stem Cell Market II-17
Other Diseases II-18
Select Key Adult Stem Cell Therapies under Development II-18
Stem Cells in Drug Discovery II-20
Tools for Drug Development II-20
5. REGULATORY ENVIRONMENT II-21
Laws Governing Stem Cells Research - The Divided World II-21
Laws and Regulations in Stem Cells Research in Select Countries
II-21
6. PRODUCT OVERVIEW II-22
Stem Cell Research II-22
Stem Cells - Description II-22
Types of Stem Cells II-22
Embryonic Stem Cells II-22
mES and hES II-22
R-NSCs II-23
Adult Stem Cells II-23
Hematopoietic Stem Cells II-24
Mesenchymal Stem Cells II-24
Umbilical Cord Stem Cells II-24
Neuronal Stem Cells II-24
Dental Stem Cells II-24
Pluripotent Adult Stem Cells II-25
Other Key Cell Types II-25
The Stem Cell Line - Cell Division II-25
Stem Cells - Properties II-26
Ability to Renew on its Own II-26
Potency II-26
Definitions of Various Potencies II-26
Identification of Stem Cells II-26
Stem Cells - Applications II-27
History of Stem Cells II-27
Stem Cells - Services and Products II-28
Significance of Stem Cell Products/Services II-28
7. RESEARCH BREAKTHROUGHS II-29
Parthenogenetic Stem Cells Holds Potential in the Treatment of
Thalassemia II-29
hESCs - A Potential Source for Unlimited Supply of Functional
Platelets II-29
Sperm-Producing Stem Cells For Diabetes Treatment -
Researchers Explore Prospects II-30
Cellonis Achieves Outstanding Results of Its Stem Cell Therapy
for Diabetes II-30
Stem Cells From Fallopian Tubes - A Prospective New Source II-30
Stem Cells from Fat - Enhancing Stem Cells Accessibility II-31
Skin Cells to Stem Cells - A New Promising Method II-31
Stem Cells to Repair Brain Damage After A Stroke II-32
ACT Shows hESCs' Potential to Become An Unlimited Source for
Functional RBCs II-32
8. PRODUCT INTRODUCTIONS/INNOVATIONS II-34
StemCells Launches New Antibody Reagents II-34
Arteriocyte Introduces Nanex Hematopoietic Stem Cell Expansion
Kit II-34
Vitrolife Unveils Growth Factors and Cytokines for Stem Cell
Cultivation II-35
BioTime to Introduce New Product Line of Stem Cell Products
II-35
Chemaphor Introduces Stem Cell Regenerative Therapy II-35
Stempeutics Research Malaysia to Launch Ischemic CS Therapy
II-35
Vitro Diagnostics Launches Novel Serum-free Stem Cell Growth
Medium II-35
ThermoGenesis to Launch Res-Q System II-36
Invitrogen to Introduce New Technology for Safe Stem Cell
Treatment II-36
Millipore Unveils MilliTrace™ Stem Cell Lines II-37
Millipore Unveils ESGRO Complete™ PLUS medium II-37
Bayer Launches Reformulated Liquid Leukine® II-37
Shenzhen Beike Biotechnology and CMC Launch NBPD's SCRM
Industrial Project II-37
Vitro Unveils New Products Supporting Stem Cell Research II-38
Endogenous Stem Cells Activators Introduces KRONOS IV II-38
ArunA Biomedical and Open Biosystems Launch iPS Kit II-39
Invitrogen Introduces Neon Transfection Device II-39
Invitrogen Introduces Xenogeneic-Free Media II-39
NanoInk Unveils NanoStem Cell Division II-39
Advanced Cell Technology Unveils New Process for Functional
Hepatocytes Generation II-40
9. RECENT INDUSTRY ACTIVITY II-41
Sanofi-Aventis Takes Over Genzyme Corporation II-41
NeoStem Merges with Progenitor Cell Therapy II-41
EHS Enters into Joint Venture with Celulas Genetica II-41
RJ to Form New Subsidiary II-41
NuPotential and VistaGen Receive NIH Grant for Development of
iPS Cells (US) II-42
BioCells Argentina Launches Dental Pulp Stem Cells Storage
Program II-42
EHSI Forges Option Deal with OceanBASIS II-42
EHSI and Regenetech Ink License Agreement II-43
Transposagen Biopharmaceuticals and CDI Ink Non-exclusive
License Agreement II-43
Kiadis Signs Licensing Agreement with Hospira to Develop and
Market Hematology Product II-43
ACT Obtains FDA Approval for Human Clinical Trials of hESCs
for Dry AMD II-44
OncoMed Commences Phase I Clinical Trial of OMP-59R5 II-44
Advanced Cell Technology and Roslin Cells Ink MoU II-44
Mesoblast Takes Over Angioblast II-45
Power3 Medical Products and Rozetta-Cell Life Sciences to Merge
II-45
University of California and BioTime Ink Material Transfer
Agreement II-45
ISCO And John Mauldin Commence Marketing Alliance for Skincare
Products II-46
Cord Blood America Inks Letter of Intent to Take Over Cryo-
Cell Mexico II-46
Mesoblast Enters into Stem Cell Marketing Deal with US Company
II-46
Bayer HealthCare Enters into Alliance with OncoMed
Pharmaceuticals II-47
SiriCell Technologies Acquires Remaining Stake in
International Stem Cell JV II-47
StemCells Receives Swissmedic Approval for Neural Stem Cells
Trial In Chronic Spinal Cord Injury II-47
ACT Obtains FDA Clearance for Human Clinical Trials of hESCs
for SMD II-48
ReNeuron Treats First Patient in Stem Cell Therapy Clinical
Trial for Stroke II-48
Amedica/US Spine Inks a Licensing and Distribution Agreement
with BioDlogics II-48
Vet-Stem Inks Sub-Licence Agreement with Australian Veterinary
Stem Cells II-49
Athersys Obtains FDA Approval for Phase II Trial for IBD Using
MultiStem® II-49
Stemedica and AnC Form Stem Cells JV II-49
Fate Therapeutics Enters into Collaboration and Licensing
Agreement with BD II-49
BrainStorm Obtains Clearance for Stem Cell Therapy Clinical
Trial for ALS in Israel II-50
Shrink Nanotechnologies Enters Final Stage of StemDisc
Commercialization II-50
Cryo-Cell's License Partner S-Evans Biosciences Opens New
Laboratory II-50
Geron Receives FDA Approval to Initiate Clinical Trials of
hESCs for Treating Acute Spinal Cord Injuries II-51
Cytori Therapeutics' Celution System Obtains European Approval
II-51
TGA Grants Approval to Mesoblast to Supply MPC Products II-51
AssureImmune and Banco Merge II-51
Salk Institute to Use Cyntellect's Cell Processing Workstation
LEAP™ II-52
STEMCELL Inks Agreement with Stanford University for Virus
Free Technique II-52
NeoStem Inks Partnership Agreement with Catholic Church II-52
Stemgent Signs Deal with Miltenyi to Co-develop and Market
Stem Cell Research Products II-52
BioTime Acquires ES Cell International II-53
Cipla Enters into Partnership with Stempeutics to Enter Stem
Cell Segment II-53
Vitro Diagnostics Signs Contract with HemoGenix II-53
Fate Acquires Verio Therapeutics II-53
Vitrolife Inks Licensing Agreement with Finn-Medi Research II-54
AXM Pharma to Establish Stem Cell Plant II-54
Stem Cell Therapy Merges with Histostem II-54
Cord Blood America Enters into Contract with BioE for Cord
Blood Processing System II-54
Pfizer Acquires Rights to Athersys' Stem Cell Therapy II-55
Enterprise Investors Acquires Large Interest in PBKM II-55
Fate Therapeutics to Distribute Stem Cell Products through
Becton Dickinson II-55
NHMC Merges with BioStem Genetics II-55
Riverside Acquires Crioestaminal II-56
Cryo-Cell International Signs Distribution Agreement with S-
Evans Biosciences II-56
Jordanian Stem Cell Purchases Stemedica International's Stem
Cell Technology II-56
BrainStorm Enters into Agreement with Protein Production
Services II-56
Novartis Acquires Opexa's Stem Cell Technology II-57
ThermoGenesis Expands Alliance with Celling Technologies II-57
Bioheart to Test MyoCell SDF-1 in REGEN Trial II-57
Osiris Initiates Enrolment for Prochymal Phase II Clinical
Trial for Type I Diabetes Treatment II-58
Stirling Divests Interest in Australian Stem Cell Healthcare
II-58
iZumi Bio Merges with Pierian II-59
iZumi Collaborates with CiRA to Expand iPSC Technology II-59
Novartis Forges Research and Development Partnership Agreement
with Epistem II-60
Healthcare of Today Acquires Regenetech II-60
Neuralstem and China Medical University to Co-develop
Treatment for Stem Cell Stroke II-60
Cytori Inks Agreement with GE Healthcare for StemSource®
Technology Commercialization II-61
MedCell Bioscience Merges with NovaThera II-61
StemCells Acquires Stem Cell Sciences II-62
BioSante Pharmaceuticals Merges with Cell Genesys II-62
Cell Therapeutics Enters into Joint Venture with Spectrum
Pharmaceuticals II-63
Cryo-Cell International Enters into Collaboration with
Cryopraxis Cryobiology II-63
Embryome Sciences Signs Partnership Agreement with
Reproductive Genetics Institute II-63
ENKAM Inks Licensing Agreement with STEMCELL II-64
Sigma-Aldrich Inks Distribution Agreement with AlphaGenix II-64
ThermoGenesis and Celling Technologies Extend Collaboration
II-65
Vivalis Enters into Collaboration with SAFC Biosciences II-65
ReNeuron Enters into Agreement with Angel Biotechnology Holdings
II-66
Cellartis Signs Agreement with ReproCELL II-66
Cellartis and AstraZeneca Extend Collaboration II-66
Embryome Sciences and Millipore Sign Co-Marketing Agreement
II-67
Cytori Enters into Partnership with GE Healthcare II-67
Stemgent Enters into Co-Exclusive Marketing Agreement with
CellDesign II-68
MultiCell Technologies and Maxim Biotech Sign R&D Agreement
II-68
GE Healthcare Collaborates with Geron Corporation II-69
Moraga Biotechnology Licenses BLSCs to Pharmacells II-69
CordLife Develops Stem Cell Therapies in India II-70
NsGene Receives European Patent Rights II-70
Pfizer to Invest in Stem Cell Research II-70
SCTI Commences Histostem Products Distribution Process II-71
Geron Secures FDA Approval for Human Trial of Embryonic Stem
Cell-Based Therapy II-71
BioE Obtains FDA Marketing Approval for PrepaCyte-CB II-72
10. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE
BUILDER II-73
StemCells Obtains FDA Approval for Phase I Clinical Trial of
HuCNS-SC® Cells in Treatment of PMD II-73
Athersys Obtains IND for Using Multistem in Treating Ischemic
Stroke II-73
Athersys Presents Initial Dosing Data of MultiStem® Phase I
Trial in AMI II-74
ACT Creates Five Lines of hESCs Without Embryo Destruction II-74
BioE Inks Agreement with StemSoft II-74
ACT's Technology Generates 140 Cell Types from hESC II-75
ACT Develops Process for Generating Functional Hepatocytes
from hESCs II-75
Applied Biosystems Merges with Invitrogen II-75
Bennett, Coleman and Co Acquires Stake in Stem One Biologicals
II-76
BMXP Holdings Acquires Freedom Environmental Services II-76
Saints Capital Completes Neuronyx Acquisition II-76
Intercity Acquires Exordia II-76
iPS and Stem Cell Merge with CDI Merge II-77
Biohellenika Acquires Exclusive Rights of Cytori's StemSource
Cell Bank II-77
International Stem Cell Signs Agreement with Millipore
Corporation II-77
ReNeuron Enters into Agreement with Angel Biotechnology II-78
ThermoGenesis and Celling Technologies Ink a Distribution
Agreement II-78
BioTime and Embryome Ink a Deal with International Stem Cell
II-79
Cryo-Cell Enters into Agreement with Saneron II-79
Genzyme Enters into Alliance with Osiris II-80
VivoMedica Enters into Collaboration with Cellartis II-80
Histostem Signs MOU with Stem Cell Therapy II-80
Vantus Inks Agreement with US Davis Center for Equine Health
II-81
Stem Cell Sciences Enters into Agreement with Pfizer II-81
Sigma-Aldrich Inks Distribution Agreement with AlphaGenix II-81
Cellartis Signs Agreement with Pfizer II-82
Ortec Changes Corporate Name to Forticell Bioscience II-82
FDA Grants Approval to Genzyme's Mozobil II-83
Pfizer Inaugurates Pfizer Regenerative Medicine Research
Facility II-83
Stem Cell Therapeutics Receives Australian Patent II-83
STEMCELL Technologies Secures License Rights to Geron IP II-84
BioTime Starts Embryonic Stem Cell Solution Facility II-85
Geron Successfully Transplants Pancreatic Islet-Like Clusters
II-85
StemCells Secures US Patent II-85
PerkinElmer Takes Over ViaCell II-85
Athersys' MultiStem® Receives US FDA Nod for Phase I Trial in
BMT Support and AMI II-86
BioE Teams Up with Phillips Plastics for Stem Cell Therapeutics
II-87
11. FOCUS ON SELECT GLOBAL PLAYERS II-88
Advanced Cell Technology, Inc. (US) II-88
Athersys, Inc. (US) II-88
BioE, Inc. (US) II-89
Cellartis AB (Sweden) II-89
Cryo-Cell International, Inc. (US) II-89
Cytori Therapeutics, Inc. (US) II-90
ES Cell International (Singapore) II-90
Gamida Cell Ltd. (Israel) II-91
Genzyme Corporation (US) II-91
Geron Corporation (US) II-91
International Stem Cell Corporation (US) II-92
Mesoblast Ltd. (Australia) II-92
Neuralstem, Inc. (US) II-93
NeuroGeneration, Inc. (US) II-93
Osiris Therapeutics, Inc. (US) II-94
StemCells, Inc. (US) II-94
ThermoGenesis Corp. (US) II-95
ViaCord, LLC (US) II-95
12. GLOBAL MARKET PERSPECTIVE II-96
Table 4: Global Recent Past, Current & Future Analysis of
Adult Stem Cell Research By Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual
Investment Figures in US$ Million for Years 2008 through 2017
(includes corresponding Graph/Chart) II-96
Table 5: World 10-Year Perspective for Adult Stem Cell
Research by Geographic Region - Percentage Breakdown of Annual
Investments for US, Europe and Rest of World Markets for Years
2008, 2011 & 2017 (includes corresponding Graph/Chart) II-97
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
North America - Spearheading Global Stem Cells Market III-1
US - The Market Leader for Stem Cell Research Worldwide III-1
Interest in Adult Stem Cell Research Continues III-2
Cosmetic Enhancements Ahead of Therapies for Diseases III-2
Embryonic Stem Cell Research in the US Held Back by Lack of
Federal Funding III-3
Vacillating US Policy on Federal Funding for hESC Research III-3
US Revokes Ban On Federal Funding for hESC Research III-3
Federal Funding Remains the Key for Further Progress in the
Sector III-4
US Court's Decree to Block Federal Funding for hESC Research
to Affect Biotech Industry III-4
Competitive Scenario III-5
Table 6: Leading Players in the US Stem Cell Therapeutics
Market (2007): Percentage Breakdown of Value Sales for
ViaCell Inc., Cryo-Cell, Osiris Therapeutics Inc.,
International Stem Cell Corporation, Geron Corp., Cytori
Therapeutics Inc., Athersys Inc., and Others (includes
corresponding Graph/Chart) III-5
B.Market Analytics III-6
Table 7: US Recent Past, Current & Future Analysis of Adult
Stem Cell Research Market Analyzed with Annual Investment
Figures in US$ Million for Years 2008 through 2017 (includes
corresponding Graph/Chart) III-6
2. EUROPE III-7
A.Market Analysis III-7
The UK Policy on hESC Remains In Favor of Developing the
Science III-7
UK Adopts Practical Approach In Addressing Moral Issues III-7
UK- The First Country to Allow Therapeutic Cloning III-7
B.Market Analytics III-8
Table 8: European Recent Past, Current & Future Analysis of
Adult Stem Cell Research Market Analyzed with Annual
Investment Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-8
3. REST OF WORLD III-9
A.Market Analysis III-9
The Rise of Asia in Stem Cells Research III-9
US Ban on Federal Funds for hESC Research Boosts Asian Presence
III-9
South Korea Pacing towards Regaining Lost Glory in Stem Cell
Research III-9
Emergence of China in the Global Stem Cell Research Space III-10
The Indian Stem Cell Research Market - An Overview III-10
B.Market Analytics III-11
Table 9: Rest of World Recent Past, Current & Future
Analysis of Adult Stem Cell Research Market Analyzed with
Annual Investment Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) III-11
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 87 (including Divisions/Subsidiaries -
92)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 62
Canada 3
Japan 1
Europe 14
France 1
The United Kingdom 7
Spain 1
Rest of Europe 5
Asia-Pacific (Excluding Japan) 9
Latin America 1
Middle East 2
Return To Main Menu Of Medical News. |
